Cargando…
Aspirin for Prevention of Preeclampsia
Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681618/ https://www.ncbi.nlm.nih.gov/pubmed/29039130 http://dx.doi.org/10.1007/s40265-017-0823-0 |
_version_ | 1783277942361554944 |
---|---|
author | Atallah, A. Lecarpentier, E. Goffinet, F. Doret-Dion, M. Gaucherand, P. Tsatsaris, V. |
author_facet | Atallah, A. Lecarpentier, E. Goffinet, F. Doret-Dion, M. Gaucherand, P. Tsatsaris, V. |
author_sort | Atallah, A. |
collection | PubMed |
description | Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to determine the effect of low-dose aspirin on the incidence of preeclampsia, with very controversial results. Large meta-analyses including individual patient data have demonstrated that aspirin is effective in preventing preeclampsia in high-risk patients, mainly those with a history of preeclampsia. However, guidelines regarding the usage of aspirin to prevent preeclampsia differ considerably from one country to another. Screening modalities, target population, and aspirin dosage are still a matter of debate. In this review, we report the pharmacodynamics of aspirin, its main effects according to dosage and gestational age, and the evidence-based indications for primary and secondary prevention of preeclampsia. |
format | Online Article Text |
id | pubmed-5681618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-56816182017-11-21 Aspirin for Prevention of Preeclampsia Atallah, A. Lecarpentier, E. Goffinet, F. Doret-Dion, M. Gaucherand, P. Tsatsaris, V. Drugs Therapy in Practice Aspirin is currently the most widely prescribed treatment in the prevention of cardiovascular complications. The indications for the use of aspirin during pregnancy are, however, the subject of much controversy. Since the first evidence of the obstetric efficacy of aspirin in 1985, numerous studies have tried to determine the effect of low-dose aspirin on the incidence of preeclampsia, with very controversial results. Large meta-analyses including individual patient data have demonstrated that aspirin is effective in preventing preeclampsia in high-risk patients, mainly those with a history of preeclampsia. However, guidelines regarding the usage of aspirin to prevent preeclampsia differ considerably from one country to another. Screening modalities, target population, and aspirin dosage are still a matter of debate. In this review, we report the pharmacodynamics of aspirin, its main effects according to dosage and gestational age, and the evidence-based indications for primary and secondary prevention of preeclampsia. Springer International Publishing 2017-10-16 2017 /pmc/articles/PMC5681618/ /pubmed/29039130 http://dx.doi.org/10.1007/s40265-017-0823-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Therapy in Practice Atallah, A. Lecarpentier, E. Goffinet, F. Doret-Dion, M. Gaucherand, P. Tsatsaris, V. Aspirin for Prevention of Preeclampsia |
title | Aspirin for Prevention of Preeclampsia |
title_full | Aspirin for Prevention of Preeclampsia |
title_fullStr | Aspirin for Prevention of Preeclampsia |
title_full_unstemmed | Aspirin for Prevention of Preeclampsia |
title_short | Aspirin for Prevention of Preeclampsia |
title_sort | aspirin for prevention of preeclampsia |
topic | Therapy in Practice |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681618/ https://www.ncbi.nlm.nih.gov/pubmed/29039130 http://dx.doi.org/10.1007/s40265-017-0823-0 |
work_keys_str_mv | AT atallaha aspirinforpreventionofpreeclampsia AT lecarpentiere aspirinforpreventionofpreeclampsia AT goffinetf aspirinforpreventionofpreeclampsia AT doretdionm aspirinforpreventionofpreeclampsia AT gaucherandp aspirinforpreventionofpreeclampsia AT tsatsarisv aspirinforpreventionofpreeclampsia |